Could a single cell infusion help newly diagnosed type 1 diabetes patients?
NCT ID NCT05626712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new treatment called CELZ-201 for people recently diagnosed with type 1 diabetes. The treatment involves a one-time infusion of cells from donated tissue into the pancreas. The main goal is to see if it is safe, but researchers will also check if it helps the body keep making its own insulin. Only 18 adults aged 18–35 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CELZ-201 (perinatal tissue derived cells)
What this could lead to
If it works, this could point toward a way to preserve insulin production in people newly diagnosed with type 1 diabetes, potentially reducing their need for insulin shots.
What could go wrong
This is a very early, small trial (18 people) focused mainly on safety. It is too soon to know if the treatment will actually help control diabetes, and there may be risks from the cell infusion or the procedure itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Diabetes Research Institute, University of Miami Miller School of Medicine
RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-••••
Contact
Contact